Invesco’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $409M | Buy |
1,671,684
+374,006
| +29% | +$81.1M | 0.03% | 437 |
|
|
2026
Q1 | $219M | Buy |
1,297,678
+24,184
| +2% | +$4.18M | 0.02% | 660 |
|
|
2025
Q4 | $233M | Buy |
1,273,494
+282,937
| +29% | +$39.5M | 0.02% | 619 |
|
|
2025
Q3 | $120M | Buy |
990,557
+419,008
| +73% | +$47.2M | 0.02% | 792 |
|
|
2025
Q2 | $59.7M | Sell |
571,549
-285,452
| -33% | -$30.2M | 0.01% | 989 |
|
|
2025
Q1 | $100M | Buy |
857,001
+164,537
| +24% | +$18.7M | 0.02% | 801 |
|
|
2024
Q4 | $58.6M | Buy |
692,464
+67,285
| +11% | +$6.19M | 0.01% | 980 |
|
|
2024
Q3 | $56.2M | Buy |
625,179
+67,318
| +12% | +$5.88M | 0.01% | 994 |
|
|
2024
Q2 | $44.9M | Buy |
557,861
+312,208
| +127% | +$23.1M | 0.01% | 1057 |
|
|
2024
Q1 | $19.6M | Buy |
245,653
+199,490
| +432% | +$16.7M | ﹤0.01% | 1466 |
|
|
2023
Q4 | $3.67M | Sell |
46,163
-16,278
| -26% | -$1.09M | ﹤0.01% | 2394 |
|
|
2023
Q3 | $4.36M | Sell |
62,441
-109,131
| -64% | -$8.16M | ﹤0.01% | 2280 |
|
|
2023
Q2 | $12.3M | Buy |
171,572
+111,045
| +183% | +$8.19M | ﹤0.01% | 1662 |
|
|
2023
Q1 | $3.73M | Sell |
60,527
-78,932
| -57% | -$5.19M | ﹤0.01% | 2359 |
|
|
2022
Q4 | $10.8M | Sell |
139,459
-31,591
| -18% | -$1.89M | ﹤0.01% | 1795 |
|
|
2022
Q3 | $7.63M | Buy |
171,050
+158,821
| +1,299% | +$7.94M | ﹤0.01% | 1967 |
|
|
2022
Q2 | $469K | Sell |
12,229
-240
| -2% | -$7.59K | ﹤0.01% | 3356 |
|
|
2022
Q1 | $516K | Buy |
12,469
+56
| +0.5% | +$1.74K | ﹤0.01% | 3372 |
|
|
2021
Q4 | $469K | Sell |
12,413
-1,192
| -9% | -$43.9K | ﹤0.01% | 3409 |
|
|
2021
Q3 | $448K | Sell |
13,605
-150,778
| -92% | -$5.88M | ﹤0.01% | 3481 |
|
|
2021
Q2 | $11.1M | Buy |
164,383
+32,250
| +24% | +$1.94M | ﹤0.01% | 1986 |
|
|
2021
Q1 | $7.48M | Sell |
132,133
-266,959
| -67% | -$18.8M | ﹤0.01% | 2142 |
|
|
2020
Q4 | $32.5M | Sell |
399,092
-28,396
| -7% | -$2.12M | 0.01% | 1194 |
|
|
2020
Q3 | $30.5M | Sell |
427,488
-71,151
| -14% | -$5.54M | 0.01% | 1119 |
|
|
2020
Q2 | $41M | Sell |
498,639
-159,583
| -24% | -$12.3M | 0.01% | 1001 |
|
|
2020
Q1 | $38.7M | Buy |
658,222
+46,863
| +8% | +$3.82M | 0.02% | 921 |
|
|
2019
Q4 | $63.2M | Sell |
611,359
-337,946
| -36% | -$13.6M | 0.02% | 896 |
|
|
2019
Q3 | $19.2M | Buy |
949,305
+141,796
| +18% | +$3.64M | 0.01% | 1434 |
|
|
2019
Q2 | $20.8M | Sell |
807,509
-242,969
| -23% | -$4.87M | 0.01% | 1412 |
|
|
2019
Q1 | $14.9M | Buy |
+1,050,478
| New | +$9.75M | 0.01% | 1385 |
|
Other funds holding AXSM
DTC
Invesco's AXSM Position: Q2 2026 in Review
Invesco increased its Axsome Therapeutics (AXSM) stake by 29% in Q2 2026, buying an estimated $81.1M and bringing the position to 1,671,684 shares worth $409M. The position accounts for 0.03% of the portfolio, ranked #437.
Invesco first reported a position in AXSM in Q1 2019 and has held it in 30 quarters since. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.
- Invesco held 1,671,684 shares of Axsome Therapeutics worth $409M as of Q2 2026.
- Invesco bought 374,006 Axsome Therapeutics shares in Q2 2026, an estimated $81.1M.
- Axsome Therapeutics made up 0.03% of Invesco's portfolio in Q2 2026, its #437 holding.
- Invesco first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 30 quarters since.
- 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.
Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.